COAGHemab Therapeutics Holdings, Inc.vs its industry peers
A metric-by-metric comparison of Hemab Therapeutics Holdings, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
Full peer comparison
Peers: same SEC industry (Biological Products, (No Diagnostic Substances))| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COAGThis | $1.7B#1 | — | — | — | — | — | — | — | — | — | — | — |
| ABOS | $189M#2 | — | 2.2x#1 | — | — | -18.6%#3 | — | -138.7%#1 | -185.6%#1 | — | 101.5%#1 | — |
| ABPO | — | — | — | — | 50.0%#1 | 218.1%#1 | -4618.6%#1 | — | — | — | — | — |
| ABPWW | $116152#3 | 0.0x#1 | — | 0.6x#1 | 50.0%#1 | 218.1%#1 | -4618.6%#1 | — | — | — | -60.9%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice